【无锡途深智合人工智能科技有限公司完成数百万元天使轮融资，加速AI蛋白质设计与优化进程】
近日，专注于人工智能蛋白质设计与优化的无锡途深智合人工智能科技有限公司及其子公司上海途深生物科技有限责任公司（简称「途深智合」）宣布，成功完成了一轮数百万元的天使轮融资，投资方为诚美资本。这一轮融资的注入，将主要用于实验室的建设和专业团队的搭建，以推动公司在人工智能驱动的蛋白质设计与合成生物领域的新产品研发。
「途深智合」成立于2023年，是一家致力于利用人工智能技术在生物科技领域进行创新的公司。其主要业务聚焦于蛋白质设计和制造，为合成生物行业提供前沿的解决方案和新产品。通过将人工智能算法与生物技术相结合，「途深智合」旨在打破传统蛋白质工程的局限，加速新药研发、生物材料制造等领域的科技进步。
诚美资本的投资，无疑是对「途深智合」在人工智能与生物科技交叉领域潜力的认可。随着实验室建设和团队建设的推进，「途深智合」有望在蛋白质工程这一关键科学领域取得更多突破，为合成生物学的发展注入新的活力，同时也为相关产业的创新和升级带来重要推动力。
此次融资事件标志着「途深智合」在人工智能驱动的生物科技赛道上迈出了坚实的步伐，预示着公司在未来将有更大的发展空间和潜力，有望在蛋白质设计与优化的前沿领域持续引领行业创新。
英语如下：
**News Title:** “TuShenZhiHe Secures Angel Round Investment for Millions, Paving the Way for a New Era in AI Protein Design”
**Keywords:** AI Protein Design, TuShenZhiHe, Angel Financing Round
**News Content:**
_Wuxi TuShenZhiHe Artificial Intelligence Technology Co., Ltd. recently completed an angel financing round worth millions of yuan, accelerating the process of AI-driven protein design and optimization._
Recently, Wuxi TuShenZhiHe Artificial Intelligence Technology Co., Ltd. and its subsidiary, Shanghai TuShen Biological Technology Co., Ltd. (collectively known as “TuShenZhiHe”), announced that they have successfully secured a million-dollar angel funding round, backed by Chengmei Capital. The funds raised will primarily be used for laboratory construction and the establishment of a professional team, driving the company’s R&D of new products in the field of protein design and synthetic biology powered by artificial intelligence.
Founded in 2023, TuShenZhiHe is a company dedicated to innovation in the biotechnology sector through the application of artificial intelligence. Its core business focuses on protein design and production, providing cutting-edge solutions and new products for the synthetic biology industry. By integrating artificial intelligence algorithms with biotechnology, TuShenZhiHe aims to overcome the limitations of traditional protein engineering, thus accelerating advancements in drug development and the production of bio materials.
The investment from Chengmei Capital underscores the recognition of TuShenZhiHe’s potential in the intersection of artificial intelligence and biotechnology. As the company progresses with laboratory development and team building, it is poised to make more breakthroughs in the crucial field of protein engineering, injecting fresh momentum into the growth of synthetic biology and contributing to innovation and upgrading in related industries.
This financing milestone signals a robust step forward for TuShenZhiHe in the biotechnology sector driven by AI, indicating substantial room for future growth and potential. The company is expected to continue leading innovation in the forefront of protein design and optimization.
【来源】https://36kr.com/p/2686282258132355
Views: 1